Reply to "Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+breast cancer"

被引：0
|
作者：
Cao, Lifen [1 ]
Stabellini, Nickolas [2 ]
Amin, Amanda L. [3 ]
Montero, Alberto J. [1 ]
机构：
[1] Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Med Ctr,Dept Med,Div Hematol & Oncol, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Cleveland, OH USA
[3] Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Med Ctr,Dept Surg,Div Surg Oncol, Cleveland, OH 44106 USA
来源：
CANCER | 2022年 / 128卷 / 16期
关键词：
D O I：
10.1002/cncr.34339
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3130 / 3130
页数：1
相关论文
共 50 条
  • [41] Effect of chemotherapy on survival in Tic-T2N0M0 medullary breast cancer: 3,976 cases from the National Cancer Data Base.
    Mateo, Aline M.
    Pezzi, Todd A.
    Pezzi, Christopher M.
    Sundermeyer, Mark
    Kelley, Cynthia A.
    Klimberg, V. Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Treatment of stage I breast cancer (T1N0M0): A long-term follow-up study
    Iturbe, J.
    Leone, J. P.
    Zwenger, A. O.
    Lacava, J. A.
    Vallejo, C. T.
    Scuteri, R. R.
    Cabaleiro, P.
    Castro, J.
    Leone, B. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis
    Petrelli, F.
    Barni, S.
    MEDICAL ONCOLOGY, 2012, 29 (04) : 2586 - 2593
  • [44] The Promher Study: An observational Italian study on HER2+ve, pT1a-b, pN0, M0 breast cancer (BC) patients (pts)
    Gori, Stefania
    Turazza, Monica
    Duranti, Simona
    Fiorio, Elena
    Foglietta, Jennifer
    Gulisano, Marcella
    Marcon, Ilaria
    Gubbiotti, Marta
    Giovanna Cavazzin, Maria
    Spazzapan, Simon
    De Simone, Valeria
    Bisagni, Giancarlo
    Saggia, Chiara
    Cavanna, Luigi
    Bria, Emilio
    Iezzi, Laura
    Cretella, Elisabetta
    Vici, Patrizia
    Santini, Daniele
    Fabi, Alessandra
    Garrone, Ornella
    Ferro, Antonella
    Saracchini, Silvana
    Evangelisti, Lucia
    Barni, Sandro
    Mentuccia, Lucia
    Laudadio, Lucio
    Inno, Alessandro
    Lunardi, Gianluigi
    Coati, Francesca
    Boni, Luca
    CANCER RESEARCH, 2015, 75
  • [45] Adjuvant chemotherapy for pT1abN0M0 triple-negative breast cancer: a systematic review and meta-analysis of published studies
    Petrelli, Fausto
    Parati, Maria Chiara
    Borgonovo, Karen
    Cabiddu, Mary
    Ghilardi, Mara
    Luciani, Andrea
    EUROPEAN JOURNAL OF CANCER, 2021, 147 : 151 - 153
  • [46] HER2 in situ hybridization analysis from 0 and 1+immunohistochemistry in breast cancer
    Heikkila, P.
    Kero, M.
    Remes, S.
    Stahls, A.
    VIRCHOWS ARCHIV, 2016, 469 : S56 - S57
  • [47] Are we overtreating patients with T1a HER2+breast cancer?: An analysis of chemotherapy use from the National Cancer Database
    Williams, Austin
    Sterbling, Helene
    Kassar, Odette
    Murray, Allison
    Sogunro, Olutayo
    De la Cruz, Lucy
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 1) : 241 - 242
  • [48] Role of HER2-neu as a prognostic factor for survival and relapse in pT1a–bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis
    F. Petrelli
    S. Barni
    Medical Oncology, 2012, 29 : 2586 - 2593
  • [49] Is there any role of adjuvant chemotherapy for T3N0M0 or T1N2M0 gastric cancer, stage II in 7th TNM but stage I in 6th TNM system?
    Lee, H. J.
    Lee, K. G.
    Suh, Y. S.
    Kong, S. H.
    Oh, D. Y.
    Im, S. A.
    Bang, Y. J.
    Yang, H. K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S424 - S424
  • [50] The Impact of Neoadjuvant Chemotherapy on Patients With T1N0M0 Triple-Negative and HER-2 Positive Breast Cancer: A Retrospective Analysis Based on the SEER Database
    Cheng, Han
    Dai, Qichen
    Liu, Gang
    Tong, Xiangyu
    Wang, Yipeng
    CLINICAL BREAST CANCER, 2024, 24 (07) : e593 - e599
12345